Lorati Company Limited has introduced a groundbreaking advancement in the treatment of age-related macular degeneration (AMD), including both dry and wet forms, with its nano-grade eye drops. Mr.

ALDX announced that the FDA has accepted its resubmitted new drug application (NDA) for reproxalap, a first-in-class ...

Whilst dry eyes can often be harmless, this symptom can also be a sign of far more serious health conditions so it is ...

Ocugen has announced positive Phase 1 trial results for OCU410, a one-time gene therapy for geographic atrophy secondary to ...

Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review. The stock rose 11% ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease. Reproxalap is a ...

Aldeyra (ALDX) announced FDA acceptance of its resubmitted market application for reproxalap and an expansion of its option agreement with AbbVie (ABBV). Read more here.

The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025, for reproxalap for patients with dry eye ...

As people, especially women, pass the age of 50, they become more at risk for Sjögren's syndrome. We asked a doctor about the ...

Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...

Chinese researchers studied 299 participants ages 18 to 45 with dry eye disease, assigning half of them to a laughter ...